Rockwell Medical's got a new Buy rating. Seems like things are looking up for them. Why? Well, their earnings outlook is improving. Analysts are revising estimates upward.

The Zacks Consensus Estimate has been on the rise lately. It's kind of a big deal. This number can really shake up stock prices.

Looking ahead to December 2025, RMTI's expected to report -$0.17 per share. No change from last year. But here's the kicker: the estimate's up 5.6% in just three months. People are getting more optimistic, it seems.

Better earnings outlook? That could be good news for the stock price. Big investors love these estimates. They crunch the numbers, and voila - higher perceived value.

Rockwell Medical's in the kidney disease and anemia game. They're sitting pretty in the top 20% of Zacks-covered stocks for estimate revisions. Not too shabby. Could mean they'll outperform soon. Maybe.

This Buy rating upgrade? It's a nod to Rockwell's business and financial outlook. Investors might want to keep an eye on this. Healthcare sector's always interesting.